← 返回

Expert Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists and the Eurasian Association of Cardio-Oncologists. "Cardioprotection 2025: Modern Approaches to Preventing Cardiotoxicity in Antitumor Therapy". Part I. Introduction, Objectives, Cardiotoxicity Detection Methods and Risk Stratification.

期刊: Kardiologiia 日期: 2025-01-01 PMID: 41294058 DOI: 10.18087/cardio.2025.10.n3076 浏览: 6
作者: Shlyakhto E V; Kaprin A D; Belenkov Yu N; Vasyuk Yu A; Khabarova N V; Ilgisonis I S; Kobalava Zh D; Koziolova N A; Tarlovskaya E I; Potievskaya V I
V, S.E., D, K.A., N, B.Y., A, V.Y., V, K.N., S, I.I., D, K.Z., A, K.N., I, T.E., & I, P.V. (2025). Expert Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists and the Eurasian Association of Cardio-Oncologists. "Cardioprotection 2025: Modern Approaches to Preventing Cardiotoxicity in Antitumor Therapy". Part I. Introduction, Objectives, Cardiotoxicity Detection Methods and Risk Stratification.. Kardiologiia. https://doi.org/10.18087/cardio.2025.10.n3076
V SE, D KA, N BY, A VY, V KN, S II, et al. Expert Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists and the Eurasian Association of Cardio-Oncologists. "Cardioprotection 2025: Modern Approaches to Preventing Cardiotoxicity in Antitumor Therapy". Part I. Introduction, Objectives, Cardiotoxicity Detection Methods and Risk Stratification.. Kardiologiia. 2025; doi: 10.18087/cardio.2025.10.n3076
V SE, D KA, N BY, et al. Expert Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists and the Eurasian Association of Cardio-Oncologists. "Cardioprotection 2025: Modern Approaches to Preventing Cardiotoxicity in Antitumor Therapy". Part I. Introduction, Objectives, Cardiotoxicity Detection Methods and Risk Stratification.[J]. Kardiologiia. 2025. DOI: 10.18087/cardio.2025.10.n3076.
@article{v2025,
  author = {Shlyakhto E V and Kaprin A D and Belenkov Yu N and Vasyuk Yu A and Khabarova N V and Ilgisonis I S and Kobalava Zh D and Koziolova N A and Tarlovskaya E I and Potievskaya V I},
  title = {Expert Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists and the Eurasian Association of Cardio-Oncologists. "Cardioprotection 2025: Modern Approaches to Preventing Cardiotoxicity in Antitumor Therapy". Part I. Introduction, Objectives, Cardiotoxicity Detection Methods and Risk Stratification.},
  journal = {Kardiologiia},
  year = {2025},
  doi = {10.18087/cardio.2025.10.n3076},
  note = {PMID: 41294058},
}
TY  - JOUR
AU  - Shlyakhto E V
AU  - Kaprin A D
AU  - Belenkov Yu N
AU  - Vasyuk Yu A
AU  - Khabarova N V
AU  - Ilgisonis I S
AU  - Kobalava Zh D
AU  - Koziolova N A
AU  - Tarlovskaya E I
AU  - Potievskaya V I
TI  - Expert Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists and the Eurasian Association of Cardio-Oncologists. "Cardioprotection 2025: Modern Approaches to Preventing Cardiotoxicity in Antitumor Therapy". Part I. Introduction, Objectives, Cardiotoxicity Detection Methods and Risk Stratification.
T2  - Kardiologiia
PY  - 2025
DO  - 10.18087/cardio.2025.10.n3076
AN  - PMID:41294058
ER  - 

摘要

The purpose of this document is to provide updated, evidence-based recommendations for the prevention of cardiovascular toxicity associated with anticancer therapy (anthracyclines, HER2-targeted therapy, tyrosine kinase inhibitors, anti-VEGF agents, fluoropyrimidines, and immune checkpoint inhibitors). The consensus covers risk stratification, screening and monitoring (biomarkers and imaging), pharmacological and non-pharmacological cardioprotection, and patient management algorithms for the detection of subclinical and clinically significant damage to the cardiovascular system. The recommendations are structured by recommendation classes (I, IIa, IIb, III) and levels of evidence (A, B, C), and are adapted for Russian and Eurasian clinical practice.

AI 智能解读

相关文献

查看原文 (DOI)
已选择 0 篇文献